J Korean Ophthalmol Soc.  2013 Feb;54(2):231-236. 10.3341/jkos.2013.54.2.231.

Effect of Sodium Hyaluronate and Cyclosporine A on Tear Film in Dry Eye Syndrome

• Chang IB
• Park JH
• Kim MS
• Kim TJ

• KMID: 2216657
• DOI: http://doi.org/10.3341/jkos.2013.54.2.231

Abstract

PURPOSE
To evaluate the efficacy of topical 0.1% hyaluronate (HA) and 0.05% cyclosporine A on tear film parameters in dry eye syndrome patients.
METHODS
Patients who were diagnosed with dry eye syndrome were treated with mbined with cyclosporine A (Group 2, 54 eyes). Ocular surface disease index (OSDI), tear film break-up time (BUT), Schirmer's test, and tear osmolarity were evaluated before treatment and at 1, 2, 3, and 6 months after treatment.
RESULTS
OSDI was significantly improved at 2 months after treatment and Schirmer's test results significantly improved at 1 month after treatment in both groups. The BUT was significantly improved 3 months after treatment in Group 1 and at 1 month after treatment in Group 2. Tear osmolarity significantly improved at 1 month after treatment in both groups, but continuously improved up to 6 months after treatment only in Group 2. The BUT and Schirmer's test showed greater improvements in Group 2 than in Group 1.
CONCLUSIONS
Combined treatment of topical 0.1% HA and 0.05% cyclosporine A may be more effective for improving dry eye syndrome.

Keyword

Cyclosporine; Dry eye syndrome; Restasis; Tear osmolarity

MeSH Terms

Cyclosporine
Dry Eye Syndromes
Humans
Hyaluronic Acid
Osmolar Concentration
Sodium
Tears
Cyclosporine
Hyaluronic Acid
Sodium

Figure

• 

  Figure 1. Changes and differences of tear osmolarity in 2 groups during follow up (mOsm/L). Mean tear osmolarity at baseline and after treatment with topical 0.1% sodium hyaluronate alone (group 1) versus after treatment with topical 0.1% sodium hyaluronate and 0.05% cyclosporine A (group 2). The decrease from baseline in tear osmolarity was statistically significant only at 1 month in group 1, then at 1, 2, 3 and 6 months in group 2. Differences of tear osmolarity in both groups were statistically significant at 3 and 6 months. ∗ p < 0.05 difference between 2 groups.

Reference

References

1. Byun YS, Jeon EJ, Chung SK. Clinical effect of cyclosporine 0.05% eye drops in dry eye syndrome patients. J Korean Ophthalmol Soc. 2008; 49:1583–8.

2. Pflugfelder SC, Tseng SC, Sanabria O, et al. Evaluation of subjective assessments and objective diagnostic tests for diagnosing tear-film disorders known to cause ocular irritation. Cornea. 1998; 17:38–56.

3. Lemp MA, Baudouin C, Baum J, et al. The definition and classification of dry eye disease: report of the Definition and Classification. Subcommittee of the International Dry Eye Work Shop (2007). Ocul Surf. 2007; 5:75–92.

4. Pflugfelder SC, Solomon A, Stern ME. The diagnosis and management of dry eye: a twenty-five-year review. Cornea. 2000; 19:644–9.

5. Stern ME, Beuerman RW, Fox RI, et al. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea. 1998; 17:584–9.

6. Stern ME, Gao J, Siemasko KF, et al. The role of the lacrimal functional unit in the pathophysiology of dry eye. Exp Eye Res. 2004; 78:409–16.

7. Smith VA, Rishmawi H, Hussein H, Easty DL. Tear film MMP accumulation and corneal disease. Br J Ophthalmol. 2001; 85:147–53.

8. Solomon A, Dursun D, Liu Z, et al. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci. 2001; 42:2283–92.

9. Argüeso P, Balaram M, Spurr-Michaud S, et al. Decreased levels of the goblet cell mucin MUC5AC in tears of patients with Sjögren syndrome. Invest Ophthalmol Vis Sci. 2002; 43:1004–11.

10. Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol. 2002; 120:330–7.

11. Hom MM. Use of cyclosporine 0.05% ophthalmic emulsion for contact lens-intolerant patients. Eye Contact Lens. 2006; 32:109–11.

12. Liu H, Begley C, Chen M, et al. A link between tear instability and hyperosmolarity in dry eye. Invest Ophthalmol Vis Sci. 2009; 50:3671–9.

13. O'Brien PD, Collum LM. Dry eye: diagnosis and current treatment strategies. Curr Allergy Asthma Rep. 2004; 4:314–9.

14. Stern ME, Pflugfelder SC. Inflammation in dry eye. Ocul Surf. 2004; 2:124–30.

15. Pflugfelder SC, Jones D, Ji Z, et al. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca. Curr Eye Res. 1999; 19:201–11.

16. Stern ME, Gao J, Schwalb TA, et al. Conjunctival T-cell sub-populations in Sjögren's and non-Sjögren's patients with dry eye. Invest Ophthalmol Vis Sci. 2002; 43:2609–14.

17. Fei WL, Chen JQ, Du X, et al. [Dry eye in graft-versus-host disease]. Zhonghua Yan Ke Za Zhi. 2003; 39:686–90.

18. Ogawa Y, Kuwana M. Dry eye as a major complication associated with chronic graft-versus-host disease after hematopoietic stem cell transplantation. Cornea. 2003; 22:S19–27.

19. Ogawa Y, Okamoto S, Wakui M, et al. Dry eye after haematopoietic stem cell transplantation. Br J Ophthalmol. 1999; 83:1125–30.

20. Lee JS, Yoon TJ, Kim KH. Cinical effect of Restasis^® eye drops in mild dry eye syndrome. J Korean Ophthalmol Soc. 2009; 50:1489–94.

21. Borel JF, Baumann G, Chapman I, et al. In vivo pharmacological effects of ciclosporin and some analogues. Adv Pharmacol. 1996; 35:115–246.

22. Laibovitz RA, Solch S, Andriano K, et al. Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca. Cornea. 1993; 12:315–23.

23. Power WJ, Mullaney P, Farrell M, Collum LM. Effect of topical cyclosporin A on conjunctival T cells in patients with secondary Sjöngren's syndrome. Cornea. 1993; 12:507–11.

24. Vanley GT, Leopold IH, Gregg TH. Interpretation of tear film breakup. Arch Ophthalmol. 1977; 95:445–8.

25. Nichols KK, Mitchell GL, Zadnik K. The repeatability of clinical measurements of dry eye. Cornea. 2004; 23:272–85.

26. Nelson JD, Wright JC. Tear film osmolality determination: an evaluation of potential errors in measurement. Curr Eye Res. 1986; 5:677–81.

27. White KM, Benjamin WJ, Hill RM. Human basic tear fluid osmolality. I. Importance of sample collection strategy. Acta Ophthalmol (Copenh). 1993; 71:524–9.

28. Gilbard JP, Farris RL, Santamaria J 2nd. Osmolarity of tear micro-volumes in keratoconjunctivitis sicca. Arch Ophthalmol. 1978; 96:677–81.

29. Tomlinson A, Khanal S, Ramaesh K, et al. Tear film osmolarity: determination of a referent for dry eye diagnosis. Invest Ophthalmol Vis Sci. 2006; 47:4309–15.

30. Wilson SE, Perry HD. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Ophthalmology. 2007; 114:76–9.

31. Barber LD, Pflugfelder SC, Tauber J, Foulks GN. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology. 2005; 112:1790–4.